Cell Therapeutics shares are trading lower following the offering news.

FORBES: Cell Therapeutics Shares Decline on Offering News

Other losers included Cell Therapeutics, which had its cancer drug rejected by the FDA, and Onyx Pharmaceuticals, which has struggled to find new growth for the cancer drug Nexavar.

FORBES

Each has demonstrated leadership in a different aspect of stem cell therapeutics and each is progressing toward an approved stem cell therapy that could have a significant effect on medical practice.

FORBES: Four Standard-Bearers For Stem Cell Therapies

Leaks have hurt other companies as well--last year, Cell Therapeutics (nasdaq: CTIC - news - people ) was hit by erroneous rumors about its drug before an important cancer meeting.

FORBES: Wyeth's Confusing Alzheimer's News

Cell Therapeutics said it intends to use net proceeds from the offering for general corporate purposes, including paying interest on or retiring outstanding debt and funding research and development, preclinical and clinical trials, and the preparation and filing of new drug applications.

FORBES: Cell Therapeutics Shares Decline on Offering News

We'd like to highlight four companies with unique approaches to stem cell therapies: Cytori Therapeutics, Geron, Athersys and Celgene.

FORBES

Notable losers in May included BioTime, a regenerative medicine firm run by Michael West, who was one of the key figures in the early days of embryonic stem cell research, and Cytori Therapeutics, which is trying to commercialize stem cells found in fat for breast reconstruction and other uses.

FORBES: Biotech Busts And Breakthroughs In May

Osiris Therapeutics is testing in new diabetics an adult stem-cell therapy that it hopes will have fewer side effects than anti-CD3 drugs.

FORBES: Magazine Article

Two researchers at Harvard's Stem Cell Institute, David Scadden and Leonard Zon, contributed two compounds in midstage human tests that Fate Therapeutics believes could prove that traditional medicines can work on stem cells.

FORBES: Magazine Article